Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Clear Cell Renal Cell Carcinoma: early-phase trial registry
14 of 46 indexed Clear Cell Renal Cell Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #312 of 28,707 conditions by registered trial count.
46 US clinical trials · 14 currently recruiting · #312 of 28,707 conditions by registered trial count
Clear Cell Renal Cell Carcinoma: 46 US clinical trials tracked, 14 recruiting.
Clear Cell Renal Cell Carcinoma is the subject of 46 registered US clinical trials on ClinicalTrials.gov, 14 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 40 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 9 of these trials.
Enrollment posture brief
Registry condition clear-cell-renal-cell-carcinoma
OPEN 14 | RECR 30% | LATE 5 | EARLY 40 | RANK #312 | SPON 9
Volume-matched condition peers
Nearest open-share peer: Anxiety Disorder (30% recruiting · 23 trials)
Clear Cell Renal Cell Carcinoma lists 14 open slots (30% of 46 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Clear Cell Renal Cell Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Clear Cell Renal Cell Carcinoma is recruiting below its size-band peers.
14 of 46 indexed trials (30.4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Clear Cell Renal Cell Carcinoma research.
National Cancer Institute (NCI) accounts for 9 of 46 trials (19.6%). 33 distinct sponsors appear on at least one study for this condition label.
-
Typical Clear Cell Renal Cell Carcinoma enrolment sits around 80 participants.
Median target enrolment is 80 among the 46 trials that report a genuine target (sentinel values excluded). 27 of those (58.7%) plan for fewer than 100 participants.
-
Clear Cell Renal Cell Carcinoma research is mostly interventional.
45 interventional and 1 observational studies make up this index (97.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
46 total, page 1 of 1
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Alliance for Clinical Trials in Oncology
NCT06661720
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Arcus Biosciences
NCT05536141
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Xencor
NCT05433142
A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Pfizer
NCT07227415
A Beta-only IL-2 ImmunoTherapY Study
Medicenna Therapeutics
NCT05086692
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
M.D. Anderson Cancer Center
NCT05663710
An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer
Jonsson Comprehensive Cancer Center
NCT06447103
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
Rahul Aggarwal
NCT03682289
Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma
University of Oklahoma
NCT07223541
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
Karie Runcie
NCT06863311
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Novelty Nobility
NCT06805825
[18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma
Orhan Kemal Oz
NCT04989959
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Neomorph
NCT07300241
Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)
M.D. Anderson Cancer Center
NCT07187778
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
National Cancer Institute (NCI)
NCT03793166
A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread
Bristol-Myers Squibb
NCT04810078
Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study
Mayo Clinic
NCT06339138
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
National Cancer Institute (NCI)
NCT02496208
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
23andMe
NCT05199272
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
National Cancer Institute (NCI)
NCT04071223
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
National Cancer Institute (NCI)
NCT01575548
A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT02293980
Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery
M.D. Anderson Cancer Center
NCT02210117
Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer
University of Southern California
NCT03092856
A Phase 1/2 Trial of ADI-270 in ccRCC
Adicet Therapeutics
NCT06480565
Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2
National Cancer Institute (NCI)
NCT03284385
Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer
Ajjai Alva, MD
NCT03308396
Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab
Mohammed Milhem
NCT05363631
Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer
Roswell Park Cancer Institute
NCT01684397
Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
NCT01038778
Prior Axitinib as a Determinant of Outcome of Renal Surgery
University of California, San Diego
NCT03438708
Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer
Emory University
NCT04022343
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
Memorial Sloan Kettering Cancer Center
NCT05239533
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
National Cancer Institute (NCI)
NCT00326898
Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors
Children's Oncology Group
NCT00335556
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer
National Cancer Institute (NCI)
NCT01835158
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Fred Hutchinson Cancer Center
NCT00027820
A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies
MedImmune
NCT02118337
Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
NCT00126594
CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)
Calithera Biosciences
NCT03163667
Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer
M.D. Anderson Cancer Center
NCT02626130
Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer
City of Hope Medical Center
NCT01157091
Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma
Arrowhead Pharmaceuticals
NCT04169711
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
CRISPR Therapeutics
NCT05795595
Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer
M.D. Anderson Cancer Center
NCT03473730
Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer
Jonsson Comprehensive Cancer Center
NCT01826877
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 24 |
| Phase 2 | 16 |
| Phase 3 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Clear Cell Renal Cell Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Clear Cell Renal Cell Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Clear Cell Renal Cell Carcinoma page
46 registered trials, 14 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 14 Clear Cell Renal Cell Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Clear Cell Renal Cell Carcinoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Clear Cell Renal Cell Carcinoma condition card totals 46 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.